Literature DB >> 19344999

Mechanisms of decreased expression of transforming growth factor-beta receptor type I at late stages of HPV16-mediated transformation.

Melissa K Hypes1, Lucia Pirisi, Kim E Creek.   

Abstract

Transforming growth factor-beta (TGF-beta) signaling is disrupted in many cancers, including cervical cancer, leading to TGF-beta resistance. Although initially sensitive, human papillomavirus type 16 (HPV16) immortalized human keratinocytes (HKc/HPV16) become increasingly resistant to the growth inhibitory effects of TGF-beta during in vitro progression to a differentiation resistant phenotype (HKc/DR). We have previously shown that loss of TGF-beta sensitivity in HKc/DR is attributed to decreased expression of TGF-beta receptor type I (TGF-beta RI), while the levels of TGF-beta receptor type II (TGF-beta RII) remain unchanged. The present study explored molecular mechanisms leading to reduced TGF-beta RI expression in HKc/DR. Using TGF-beta RI and TGF-beta RII promoter reporter constructs, we determined that acute expression of the HPV16 oncogenes E6 and E7 decreased the promoter activity of TGF-beta RI and TGF-beta RII by about 50%. However, promoter activity of TGF-beta RI is decreased to a greater extent than TGF-beta RII as HKc/HPV16 progress to HKc/DR. Reduced TGF-beta RI expression in HKc/DR was found not to be linked to mutations within the TGF-beta RI promoter or to promoter methylation. Electrophoretic mobility shift and supershift assays using probes encompassing Sp1 binding sites in the TGF-beta RI promoter found no changes between HKc/HPV16 and HKc/DR in binding of the transcription factors Sp1 or Sp3 to the probes. Also, Western blots determined that protein levels of Sp1 and Sp3 remain relatively unchanged between HKc/HPV16 and HKc/DR. Overall, these results demonstrate that mutations in or hypermethylation of the TGF-beta RI promoter, along with altered levels of Sp1 or Sp3, are not responsible for the reduced expression of TGF-beta RI we observe in HKc/DR. Rather the HPV16 oncogenes E6 and E7 themselves exhibit an inhibitory effect on TGF-beta receptor promoter activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344999      PMCID: PMC2710415          DOI: 10.1016/j.canlet.2009.03.014

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  35 in total

1.  Sp3 is a transcriptional repressor of transforming growth factor-beta receptors.

Authors:  S Ammanamanchi; M G Brattain
Journal:  J Biol Chem       Date:  2000-10-10       Impact factor: 5.157

2.  Reversion of transcriptional repression of Sp1 by 5 aza-2' deoxycytidine restores TGF-beta type II receptor expression in the pancreatic cancer cell line MIA PaCa-2.

Authors:  K Venkatasubbarao; S Ammanamanchi; M G Brattain; D Mimari; J W Freeman
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

Review 3.  Regulation of the activity of Sp1-related transcription factors.

Authors:  Peter Bouwman; Sjaak Philipsen
Journal:  Mol Cell Endocrinol       Date:  2002-09-30       Impact factor: 4.102

4.  5-azaC treatment enhances expression of transforming growth factor-beta receptors through down-regulation of Sp3.

Authors:  S Ammanamanchi; M G Brattain
Journal:  J Biol Chem       Date:  2001-07-06       Impact factor: 5.157

Review 5.  Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation.

Authors:  Aristidis Moustakas; Katerina Pardali; Annamaria Gaal; Carl Henrik Heldin
Journal:  Immunol Lett       Date:  2002-06-03       Impact factor: 3.685

6.  Retinoic acid resistance at late stages of human papillomavirus type 16-mediated transformation of human keratinocytes arises despite intact retinoid signaling and is due to a loss of sensitivity to transforming growth factor-beta.

Authors:  D R Borger; Y Mi; G Geslani; L L Zyzak; A Batova; T S Engin; L Pirisi; K E Creek
Journal:  Virology       Date:  2000-05-10       Impact factor: 3.616

7.  Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency.

Authors:  S Periyasamy; S Ammanamanchi; M P Tillekeratne; M G Brattain
Journal:  Oncogene       Date:  2000-09-21       Impact factor: 9.867

8.  Identification of genetic alterations in the TGFbeta type II receptor gene promoter.

Authors:  E R Seijo; H Song; M A Lynch; R Jennings; X Qong; E Lazaridis; C Muro-Cacho; C M Weghorst; T Muñoz-Antonia
Journal:  Mutat Res       Date:  2001-11-01       Impact factor: 2.433

Review 9.  TGF-beta and the Smad signal transduction pathway.

Authors:  Arun Mehra; Jeffrey L Wrana
Journal:  Biochem Cell Biol       Date:  2002       Impact factor: 3.626

Review 10.  Human papillomaviruses, cervical cancer and cell polarity.

Authors:  M Thomas; N Narayan; D Pim; V Tomaić; P Massimi; K Nagasaka; C Kranjec; N Gammoh; L Banks
Journal:  Oncogene       Date:  2008-11-24       Impact factor: 9.867

View more
  12 in total

1.  Ski protein levels increase during in vitro progression of HPV16-immortalized human keratinocytes and in cervical cancer.

Authors:  Yi Chen; Lucia Pirisi; Kim E Creek
Journal:  Virology       Date:  2013-06-27       Impact factor: 3.616

Review 2.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

3.  Induction of Interferon Kappa in Human Papillomavirus 16 Infection by Transforming Growth Factor Beta-Induced Promoter Demethylation.

Authors:  Brittany L Woodby; William K Songock; Matthew L Scott; Gaurav Raikhy; Jason M Bodily
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

Review 4.  Transforming growth factor-β1 in carcinogenesis, progression, and therapy in cervical cancer.

Authors:  Haiyan Zhu; Hui Luo; Zhaojun Shen; Xiaoli Hu; Luzhe Sun; Xueqiong Zhu
Journal:  Tumour Biol       Date:  2016-03-24

Review 5.  The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.

Authors:  B Woodby; M Scott; J Bodily
Journal:  Prog Mol Biol Transl Sci       Date:  2016-10-11       Impact factor: 3.622

6.  Six1 overexpression at early stages of HPV16-mediated transformation of human keratinocytes promotes differentiation resistance and EMT.

Authors:  Hanwen Xu; Lucia Pirisi; Kim E Creek
Journal:  Virology       Date:  2014-11-17       Impact factor: 3.616

7.  TGF-β regulation of gene expression at early and late stages of HPV16-mediated transformation of human keratinocytes.

Authors:  Sangeeta Kowli; Rupa Velidandla; Kim E Creek; Lucia Pirisi
Journal:  Virology       Date:  2013-09-19       Impact factor: 3.616

8.  Inhibition of Epstein-Barr Virus Replication in Human Papillomavirus-Immortalized Keratinocytes.

Authors:  J T Guidry; J E Myers; M Bienkowska-Haba; W K Songock; X Ma; M Shi; C O Nathan; J M Bodily; M J Sapp; R S Scott
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

9.  Epigenetic Alteration by DNA Promoter Hypermethylation of Genes Related to Transforming Growth Factor-β (TGF-β) Signaling in Cancer.

Authors:  Sann Sanda Khin; Riko Kitazawa; Takeshi Kondo; Yuka Idei; Masayo Fujimoto; Ryuma Haraguchi; Kiyoshi Mori; Sohei Kitazawa
Journal:  Cancers (Basel)       Date:  2011-03-03       Impact factor: 6.639

10.  Partial loss of Smad signaling during in vitro progression of HPV16-immortalized human keratinocytes.

Authors:  Diego Altomare; Rupa Velidandla; Lucia Pirisi; Kim E Creek
Journal:  BMC Cancer       Date:  2013-09-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.